{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:35:35Z","timestamp":1784662535375,"version":"3.55.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clon.2023.03.001","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T20:39:16Z","timestamp":1678221556000},"page":"548-555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Health Services Research in Brachytherapy: Current Understanding and Future Challenges"],"prefix":"10.1016","volume":"35","author":[{"given":"N.","family":"Defourny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clon.2023.03.001_bib1","first-page":"737","article-title":"Brachytherapy \u2013 a dose of pragmatism needed","volume":"22","author":"The Lancet Oncology","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.03.001_bib2","series-title":"The GEC-ESTRO Handbook of Brachytherapy;","author":"GEC-ESTRO","year":"2019"},{"key":"10.1016\/j.clon.2023.03.001_bib3","series-title":"Oncology, N.C.G.i. Cervical Cancer;","author":"National Comprehensive Cancer Network","year":"2021"},{"key":"10.1016\/j.clon.2023.03.001_bib4","series-title":"Oncology, N.C.G.i. Uterine Cancer;","author":"National Comprehensive Cancer Network","year":"2022"},{"key":"10.1016\/j.clon.2023.03.001_bib5","series-title":"NCCN guideline: Prostate Cancer;","author":"National Comprehensive Cancer Network","year":"2022"},{"issue":"1","key":"10.1016\/j.clon.2023.03.001_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.brachy.2011.08.005","article-title":"American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy","volume":"11","author":"Small","year":"2012","journal-title":"Brachytherapy"},{"issue":"1","key":"10.1016\/j.clon.2023.03.001_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brachy.2011.07.002","article-title":"American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy","volume":"11","author":"Viswanathan","year":"2012","journal-title":"Brachytherapy"},{"issue":"1","key":"10.1016\/j.clon.2023.03.001_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.brachy.2011.09.008","article-title":"American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy","volume":"11","author":"Yamada","year":"2012","journal-title":"Brachytherapy"},{"issue":"1","key":"10.1016\/j.clon.2023.03.001_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2011.07.005","article-title":"American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy","volume":"11","author":"Davis","year":"2012","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.clon.2023.03.001_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.brachy.2018.11.009","article-title":"Brachytherapy: a critical component of primary radiation therapy for cervical cancer: from the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS)","volume":"18","author":"Holschneider","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.clon.2023.03.001_bib11","series-title":"eviQ. Gynaecological malignancies","author":"Cancer Institute","year":"2022"},{"key":"10.1016\/j.clon.2023.03.001_bib12","series-title":"eviQ. Prostate cancer","author":"Cancer Institute","year":"2016"},{"issue":"1","key":"10.1016\/j.clon.2023.03.001_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2013.05.033","article-title":"Trends in the utilization of brachytherapy in cervical cancer in the United States","volume":"87","author":"Han","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.clon.2023.03.001_bib14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0360-3016(91)90007-Q","article-title":"Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 patterns of care studies","volume":"20","author":"Lanciano","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.clon.2023.03.001_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ygyno.2016.09.009","article-title":"Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer","volume":"143","author":"Robin","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.clon.2023.03.001_bib16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-018-0310-8","article-title":"Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy","volume":"119","author":"Wortman","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.clon.2023.03.001_bib17","first-page":"16","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"26","key":"10.1016\/j.clon.2023.03.001_bib18","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1200\/JCO.2015.62.5459","article-title":"Postoperative radiation therapy for endometrial cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based guideline","volume":"33","author":"Meyer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.clon.2023.03.001_bib19","first-page":"386","article-title":"Brachytherapy: an overview for clinicians","volume":"69","author":"Chargari","year":"2019","journal-title":"CA: Cancer J Clin"},{"issue":"5","key":"10.1016\/j.clon.2023.03.001_bib20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ijrobp.2014.07.017","article-title":"National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements","volume":"90","author":"Gill","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9717","key":"10.1016\/j.clon.2023.03.001_bib21","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clon.2023.03.001_bib22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.clon.2023.03.001_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2023.03.001_bib24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2023.03.001_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","article-title":"Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int"},{"issue":"15","key":"10.1016\/j.clon.2023.03.001_bib26","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.clon.2023.03.001_bib27","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/JCO.21.00855","article-title":"Short androgen suppression and radiation dose escalation in prostate cancer: 12-year results of EORTC trial 22991 in patients with localized intermediate-risk disease","volume":"39","author":"Bolla","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.clon.2023.03.001_bib28","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1002\/cncr.22337","article-title":"Estimation of the optimal brachytherapy utilization rate in the treatment of carcinoma of the uterine cervix: review of clinical practice guidelines and primary evidence","volume":"107","author":"Thompson","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clon.2023.03.001_bib29","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ijrobp.2008.01.022","article-title":"Estimation of optimal brachytherapy utilization rate in the treatment of malignancies of the uterine corpus by a review of clinical practice guidelines and the primary evidence","volume":"72","author":"Thompson","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clon.2023.03.001_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.radonc.2015.12.023","article-title":"Estimation of the optimal utilisation rates of radical prostatectomy, external beam radiotherapy and brachytherapy in the treatment of prostate cancer by a review of clinical practice guidelines","volume":"118","author":"Thompson","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2023.03.001_bib31","first-page":"1","article-title":"External radiation and brachytherapy resource deficit for cervical cancer in India: call to action for treatment of all","volume":"5","author":"Chopra","year":"2019","journal-title":"J\u00a0Glob Oncol"},{"issue":"1","key":"10.1016\/j.clon.2023.03.001_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.radonc.2015.04.018","article-title":"The optimal utilization proportion of external beam radiotherapy in European countries: an ESTRO-HERO analysis","volume":"116","author":"Borras","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2023.03.001_bib33","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0167-8140(17)30566-2","article-title":"SP-0124: Optimal utilisation of brachytherapy in Europe. Can it be measured?","volume":"123","author":"Borras","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2023.03.001_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2022.100333","article-title":"Lessons from the Brazilian radiotherapy expansion plan: a project database study","volume":"14","author":"Hanna","year":"2022","journal-title":"Lancet Regional Health-Americas"},{"issue":"7","key":"10.1016\/j.clon.2023.03.001_bib35","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S1470-2045(19)30308-0","article-title":"Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact","volume":"20","author":"Rodin","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clon.2023.03.001_bib36","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s12094-009-0398-7","article-title":"Brachytherapy in the United Kingdom and Spain: a subset analysis of a European pattern of care survey","volume":"11","author":"Guedea","year":"2009","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clon.2023.03.001_bib37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.radonc.2020.07.010","article-title":"Brachytherapy in Belgium in 2018. A national survey of the brachytherapy study group of the Belgian SocieTy for\u00a0Radiotherapy and Oncology (BeSTRO)","volume":"150","author":"Salembier","year":"2020","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.clon.2023.03.001_bib38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.brachy.2016.12.015","article-title":"Brachytherapy boost for prostate cancer: trends in care and survival outcomes","volume":"16","author":"Glaser","year":"2017","journal-title":"Brachytherapy"},{"issue":"6","key":"10.1016\/j.clon.2023.03.001_bib39","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.brachy.2016.05.001","article-title":"The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness","volume":"15","author":"Orio","year":"2016","journal-title":"Brachytherapy"},{"issue":"6","key":"10.1016\/j.clon.2023.03.001_bib40","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.brachy.2021.07.002","article-title":"Utilization of brachytherapy in Quebec, Canada","volume":"20","author":"Lecavalier-Barsoum","year":"2021","journal-title":"Brachytherapy"},{"issue":"6","key":"10.1016\/j.clon.2023.03.001_bib41","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.3802\/jgo.2021.32.e85","article-title":"Brachytherapy utilization rate and effect on survival in cervical cancer patients in Korea","volume":"32","author":"Kim","year":"2021","journal-title":"J\u00a0Gynecol Oncol"},{"key":"10.1016\/j.clon.2023.03.001_bib42","series-title":"Economic analysis in healthcare","author":"Morris","year":"2012"},{"issue":"2","key":"10.1016\/j.clon.2023.03.001_bib43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jval.2017.12.008","article-title":"Objectives, budgets, thresholds, and opportunity costs \u2014 a health economics approach: an ISPOR Special Task Force report [4]","volume":"21","author":"Danzon","year":"2018","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.clon.2023.03.001_bib44","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40258-014-0106-9","article-title":"Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013","volume":"12","author":"Amin","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"10.1016\/j.clon.2023.03.001_bib45","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(19)30794-6","article-title":"How public health services pay for radiotherapy in Europe: an ESTRO\u2013HERO analysis of reimbursement","volume":"21","author":"Lievens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.03.001_bib46","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.semradonc.2019.08.007","article-title":"The cost-effectiveness and value proposition of brachytherapy","volume":"30","author":"Vu","year":"2020","journal-title":"Semin Radiat Oncol"},{"issue":"3","key":"10.1016\/j.clon.2023.03.001_bib47","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.radonc.2016.12.002","article-title":"Cost evaluations of radiotherapy: what do we know? An ESTRO-HERO analysis","volume":"121","author":"Defourny","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2023.03.001_bib48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2019.06.015","article-title":"National costs and resource requirements of external beam radiotherapy: a time-driven activity-based costing model from the ESTRO-HERO project","volume":"138","author":"Defourny","year":"2019","journal-title":"Radiother Oncol"},{"issue":"9","key":"10.1016\/j.clon.2023.03.001_bib49","first-page":"46","article-title":"How to solve the cost crisis in health care","volume":"89","author":"Kaplan","year":"2011","journal-title":"Harv Bus Rev"},{"issue":"5","key":"10.1016\/j.clon.2023.03.001_bib50","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1200\/JOP.2015.008441","article-title":"Time-driven activity-based costing: a comparative cost analysis of whole-breast radiotherapy versus balloon-based brachytherapy in the management of early-stage breast cancer","volume":"12","author":"Schutzer","year":"2016","journal-title":"J\u00a0Oncol Pract"},{"issue":"6","key":"10.1016\/j.clon.2023.03.001_bib51","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.brachy.2016.08.008","article-title":"Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer","volume":"15","author":"Ilg","year":"2016","journal-title":"Brachytherapy"},{"issue":"4","key":"10.1016\/j.clon.2023.03.001_bib52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.prro.2021.01.003","article-title":"Examining the financial impact of altered fractionation in breast cancer: an analysis using time-driven activity-based costing","volume":"11","author":"Dziemianowicz","year":"2021","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"10.1016\/j.clon.2023.03.001_bib53","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1017\/S026646230707033X","article-title":"Implications of learning effects for hospital costs of new health technologies: the case of intensity modulated radiation therapy","volume":"23","author":"Bonastre","year":"2007","journal-title":"Int J Technol Assess Health Care"},{"issue":"3","key":"10.1016\/j.clon.2023.03.001_bib54","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijrobp.2014.10.014","article-title":"The case for prostate brachytherapy in the Affordable Care Act era","volume":"91","author":"Durkee","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.clon.2023.03.001_bib55","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.clon.2017.11.015","article-title":"A\u00a0cost-effectiveness analysis of contact X-ray brachytherapy for the treatment of patients with rectal cancer following a partial response to chemoradiotherapy","volume":"30","author":"Rao","year":"2018","journal-title":"Clin Oncol"},{"issue":"8","key":"10.1016\/j.clon.2023.03.001_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014944","article-title":"Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom","volume":"7","author":"Vaidya","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.clon.2023.03.001_bib57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) \u2013 explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.clon.2023.03.001_bib58","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1186\/s12913-016-1781-z","article-title":"Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review","volume":"16","author":"Becerra","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clon.2023.03.001_bib59","series-title":"High dose rate brachytherapy versus low dose rate brachytherapy for the treatment of prostate cancer: a review of clinical effectiveness and cost-effectiveness","author":"Gray","year":"2019"},{"key":"10.1016\/j.clon.2023.03.001_bib60","first-page":"76","article-title":"Maximizing resources in the local treatment of prostate cancer: a summary of cost-effectiveness studies","volume":"35","author":"Muralidhar","year":"2017","journal-title":"Urol Oncol Semin Orig Invest"},{"issue":"3","key":"10.1016\/j.clon.2023.03.001_bib61","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s41669-020-00250-7","article-title":"National healthcare economic evaluation guidelines: a cross-country comparison","volume":"5","author":"Sharma","year":"2021","journal-title":"Pharmacoecon Open"},{"issue":"6","key":"10.1016\/j.clon.2023.03.001_bib62","doi-asserted-by":"crossref","first-page":"503","DOI":"10.5114\/jcb.2018.79928","article-title":"Cost in perspective: direct assessment of American market acceptability of Co-60 in gynecologic high-dose-rate brachytherapy and contrast with experience abroad","volume":"10","author":"Mailhot Vega","year":"2018","journal-title":"J\u00a0Contemp Brachyther"},{"key":"10.1016\/j.clon.2023.03.001_bib63","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.radonc.2021.11.035","article-title":"Variable and fixed costs in NHS radiotherapy; consequences for increasing hypo fractionation","volume":"166","author":"Spencer","year":"2022","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.clon.2023.03.001_bib64","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.clon.2016.11.010","article-title":"Who should bear the cost of convenience? A cost-effectiveness analysis comparing external beam and brachytherapy radiotherapy techniques for early stage breast cancer","volume":"29","author":"McGuffin","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2023.03.001_bib65","series-title":"NICE health technology evaluations: the manual","year":"2022"},{"issue":"3","key":"10.1016\/j.clon.2023.03.001_bib66","doi-asserted-by":"crossref","first-page":"331","DOI":"10.5114\/jcb.2014.45761","article-title":"Brachytherapy in India \u2013 a long road ahead","volume":"6","author":"Banerjee","year":"2014","journal-title":"J\u00a0Contemp Brachyther"},{"key":"10.1016\/j.clon.2023.03.001_bib67","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/1754-9485.13424","article-title":"Survey of brachytherapy training experience among radiation oncology trainees and fellows in the Royal Australian and New Zealand College of Radiologists (RANZCR)","volume":"66","author":"Ong","year":"2022","journal-title":"J\u00a0Med Imag Radiat Oncol"},{"issue":"1","key":"10.1016\/j.clon.2023.03.001_bib68","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13246-016-0430-5","article-title":"Brachytherapy: a dying art or missed opportunity?","volume":"39","author":"Haworth","year":"2016","journal-title":"Austral Phys Engineer Sci Med"},{"issue":"9444","key":"10.1016\/j.clon.2023.03.001_bib69","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0140-6736(04)17272-3","article-title":"Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial","volume":"364","author":"Homs","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clon.2023.03.001_bib70","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5114\/jcb.2017.67147","article-title":"High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art \u2013 a single institute experience","volume":"9","author":"Bhalavat","year":"2017","journal-title":"J\u00a0Contemp Brachyther"},{"issue":"5","key":"10.1016\/j.clon.2023.03.001_bib71","doi-asserted-by":"crossref","first-page":"454","DOI":"10.5114\/jcb.2018.79399","article-title":"A\u00a0systematic review of treating recurrent head and neck cancer: a reintroduction of brachytherapy with or without surgery","volume":"10","author":"Rodin","year":"2018","journal-title":"J\u00a0Contemp Brachyther"},{"issue":"4","key":"10.1016\/j.clon.2023.03.001_bib72","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S2468-1253(21)00004-2","article-title":"Palliative radiotherapy after oesophageal cancer stenting\u00a0(ROCS): a multicentre, open-label, phase 3 randomised\u00a0controlled trial","volume":"6","author":"Adamson","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clon.2023.03.001_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.11.022","article-title":"Planned organ preservation for early T2-3 rectal\u00a0adenocarcinoma: a French, multicentre study","volume":"108","author":"G\u00e9rard","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.clon.2023.03.001_bib74","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S1470-2045(21)00720-8","article-title":"Cancer in sub-Saharan Africa: a Lancet Oncology Commission","volume":"23","author":"Ngwa","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.03.001_bib75","article-title":"Adopting health economic research in radiation oncology: a perspective from low- or middle-income countries","volume":"8","author":"Sinha","year":"2022","journal-title":"JCO Glob Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523000857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523000857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:53:18Z","timestamp":1760543598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655523000857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":75,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0936655523000857"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2023.03.001","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Services Research in Brachytherapy: Current Understanding and Future Challenges","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2023.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}